DaVita Inc. (NYSE:DVA - Get Free Report) has earned an average rating of "Hold" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $164.50.
Several research firms recently commented on DVA. Truist Financial cut their price objective on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th.
Read Our Latest Research Report on DaVita
Hedge Funds Weigh In On DaVita
A number of hedge funds have recently modified their holdings of the company. Wellington Management Group LLP boosted its position in shares of DaVita by 9.1% during the fourth quarter. Wellington Management Group LLP now owns 2,711 shares of the company's stock worth $405,000 after acquiring an additional 227 shares during the last quarter. Fifth Third Bancorp boosted its position in shares of DaVita by 5.0% during the first quarter. Fifth Third Bancorp now owns 4,274 shares of the company's stock worth $654,000 after acquiring an additional 204 shares during the last quarter. Concurrent Investment Advisors LLC bought a new position in shares of DaVita during the first quarter worth $223,000. Wealth Enhancement Advisory Services LLC lifted its position in DaVita by 22.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,351 shares of the company's stock valued at $666,000 after purchasing an additional 800 shares during the last quarter. Finally, OneDigital Investment Advisors LLC bought a new position in DaVita during the first quarter valued at $200,000. 90.12% of the stock is currently owned by institutional investors.
DaVita Stock Up 2.2%
DaVita stock opened at $143.35 on Friday. DaVita has a twelve month low of $131.76 and a twelve month high of $179.60. The firm has a 50 day moving average price of $140.16 and a 200-day moving average price of $148.63. The company has a market capitalization of $10.82 billion, a P/E ratio of 14.21, a P/E/G ratio of 0.98 and a beta of 1.11. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 23.18.
DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping the consensus estimate of $1.75 by $0.25. The company had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a net margin of 6.63% and a return on equity of 176.11%. DaVita's revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the firm earned $2.26 EPS. As a group, equities analysts predict that DaVita will post 10.76 EPS for the current year.
DaVita Company Profile
(
Get Free ReportDaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.